Advertisement

Topics

Acousia Therapeutics GmbH Company Profile

08:20 EDT 20th September 2018 | BioPortfolio


News Articles [905 Associated News Articles listed on BioPortfolio]

Protecting Against Hearing Loss: Acousia Pursues A New Approach

German biotech Acousia Therapeutics closes a series B round with corporate and institutional VC firms, and aims to advance its...   

Acousia Therapeutics Announces €10 Million Series B Financing to Advance its Hearing Loss Portfolio

Acousia Therapeutics (Acousia), a leader in the discovery and development of novel therapies in inner ear-related diseases and pathologies, today announced the closing of a €10 ...

Acousia raises €10M in series B

Acousia raises $12M in series B

Acousia raises $11.9M in series B

Topas Therapeutics GmbH: Topas Therapeutics and Boehringer Ingelheim Sign Multi-Year Collaboration and Option Agreement

Companies join forces in immune tolerance to tackle ADA (anti-drug antibodies) Initial focus on next generation vector-based therapeutics Boehringer Ingelheim is granted option to in-license sever...

Systec GmbH Introduces its new Business Partner Evidencia GmbH

Research, pharmaceuticals, life sciences and food: many laboratories rely on steam sterilizers or equipment where processes are monitored using pressure and temperature control. Thanks to our collabor...

Royalties under patent licence agreements: can they remain payable even if the licensed patents(s) are revoked or not practised? Lessons from Genentech Inc v Hoechst GmbH & Sanofi-Aventis Deutschland GmbH

Précis In its recent decision in Genentech Inc v Hoechst GmbH & Sanofi-Aventis Deutschland GmbH (7 July 2016), the Court of Justice of the EU (“CJEU”) has ruled that an obligati...

PubMed Articles [443 Associated PubMed Articles listed on BioPortfolio]

Correction to: Lonoctocog Alfa: A Review in Haemophilia A.

The article Lonoctocog Alfa: A Review in Haemophilia A, written by Zaina T. Al-Salama and Lesley J. Scott, was originally published Online First without open access. After publication in volume 77...

RNA Therapeutics (Almost) Comes of Age: Targeting, Delivery and Endosomal Escape.

Recent developments in intracellular protein delivery.

Protein therapeutics based on transcription factors, gene editing enzymes, signaling proteins and protein antigens, have the potential to provide cures for a wide number of untreatable diseases, but c...

A Review of Therapeutics in Clinical Development for Respiratory Syncytial Virus and Influenza in Children.

Respiratory syncytial virus (RSV) and influenza are important viral pathogens worldwide. Children, in particular, bear considerable burdens of morbidity and mortality associated with these viruses. Th...

Ocular Impression-Taking-Which Material Is Best?

To assess the efficacy and effect on clinical signs of a polyvinylsiloxane (Tresident; Shütz Dental Group GmbH, Germany) compared with an irreversible hydrocolloid (Orthoprint; Zhermack SpA, Badia Po...

Clinical Trials [200 Associated Clinical Trials listed on BioPortfolio]

Bioequivalence Study Comparing Two Test Products With One Reference Product, All Containing 5 mg Yohimbine

- Type: Bioequivalence study in male healthy volunteers, therapeutical indication (erectile disfunction) not studied - Products, dosage, and route of administration: ...

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

XC8 in the Treatment of Patients With Bronchial Asthma

A multicenter, double-blind, randomized, parallel-group comparative Phase II clinical study to assess the efficacy and safety of different doses of XC8 vs Placebo in patients with partly c...

Companies [1779 Associated Companies listed on BioPortfolio]

Acousia Therapeutics GmbH

SCT Spinal Cord Therapeutics GmbH

SCT Spinal Cord Therapeutics GmbH stands for pioneering the therapy of acute and chronic Spinal Cord Injuries (SCI) with its proprietary technology platform: the Regeneration Promoting Treatment (RPT)...

Chemie-Kontor GmbH

Chemie-Kontor GmbH trades with chemical specialities for customers in Pharma-, Agro-, Cosmetics and Nutrition Industries and offers a broad range of services. Chemie-Kontor GmbH is agent for: Amberger...

Isarna Therapeutics GmbH

Isarna Therapeutics has an unmatched commitment to developing TGF-β inhibitors that stimulate the human immune system to effectively fight cancer. Isarna Therapeutics are advancing a unique pip...

OctreoPharm Sciences GmbH

OctreoPharm Sciences GmbH, located in Berlin (Germany) is a privately held clinical development company focusing on radiopharmaceuticals for the diagnosis and therapeutic control ...

More Information about "Acousia Therapeutics GmbH" on BioPortfolio

We have published hundreds of Acousia Therapeutics GmbH news stories on BioPortfolio along with dozens of Acousia Therapeutics GmbH Clinical Trials and PubMed Articles about Acousia Therapeutics GmbH for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Acousia Therapeutics GmbH Companies in our database. You can also find out about relevant Acousia Therapeutics GmbH Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record